REGISTER
Hengrui NewCo Heads for Nasdaq IPO; Insilico Strikes Two Major Deals
This week: NMPA approved camrelizumab plus famitinib for first-line cervical cancer (PFS 11.1 vs 7.5 mo; OS 34.4 vs 23.4 mo in 443 patients); FDA approved LIPFENDRA, the first oral PCSK9 inhibitor (56-59% LDL-C reduction at 24 weeks); GSK dropped camlipixant for chronic cough after mixed Phase 3; key deals included Hengrui’s HRS-1893 NewCo Braveheart Bio Nasdaq filing, Insilico’s two collaborations over $2.5B, Dizal’s $1.5B AstraZeneca deal for sunvozertinib ($600M upfront), and Innovent’s $1.1B

On 16 July, the NMPA announced a new indication for Hengrui Pharma’s camrelizumab, in combination with famitinib for the first-line treatment of recurrent or metastatic cervical cancer — making it the first domestic PD-1 monoclonal antibody to receive first-line cervical cancer approval in China. The approval is based on the Phase 3 SHR-1210-III-329 registrational data, a multicenter study that enrolled 443 patients with a median follow-up of 19.3 months. Compared with standard platinum-containing chemotherapy, the immune-targeted combination regimen significantly extended survival: median PFS reached 11.1 months (versus 7.5 months with chemotherapy, a 32% reduction in the risk of progression), and median OS exceeded 34.4 months (versus 23.4 months with chemotherapy, a 35% reduction in the risk of death), with consistent benefit across the full study population and offering a new chemotherapy-free first-line option. The camrelizumab plus famitinib combination has previously been approved in a later-line cervical cancer indication; this approval moves the regimen to an earlier line.

Camrelizumab’s domestic indications now total 11, covering multiple solid tumors, further consolidating the lead position of domestic immune checkpoint inhibitors in gynecologic oncology and enriching the standardized treatment landscape for advanced cervical cancer.

Dosage-Form Breakthrough: The World’s First Oral PCSK9 Inhibitor Approved by the FDA

On 17 July, Merck (MSD) announced that the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA 20 mg tablets as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

The product is a novel macrocyclic peptide and the first oral PCSK9 inhibitor approved globally, breaking the long-standing injectable-only paradigm for this target and enabling once-daily oral dosing that substantially improves patient adherence. The approval is supported by two pivotal Phase 3 trials in the CORALreef program: at 24 weeks, the drug reduced LDL-C by up to 56% versus placebo in the general hypercholesterolemia population, and by up to 59% in HeFH patients, while significantly reducing atherogenic lipid markers such as apolipoprotein B (ApoB). Overall safety was comparable to placebo, with no meaningful difference in adverse-event-related discontinuation rates. Previously, the PCSK9 space was entirely dominated by injectable monoclonal antibodies; the introduction of an oral macrocyclic peptide opens an entirely new path for lipid-lowering therapy and may reshape the competitive landscape of cardiovascular lipid-lowering drugs.

Clinical Data Readout:

Phase 3 Misses Expectations, GSK Discontinues Lead P2X3 Antitussive for Chronic Cough

On 17 July, GSK announced full data from the two pivotal Phase 3 trials CALM-1 and CALM-2 of camlipixant, a highly selective P2X3 receptor antagonist, in adults with refractory chronic cough (RCC), and disclosed that the company is stopping all further development of the drug in RCC. The two trials tested 25 mg and 50 mg twice-daily dosing, with the primary endpoint of reduction in 24-hour cough frequency versus placebo. In the 12-week short-term CALM-1 trial, the 50 mg dose met the primary endpoint, but the 24-week long-term CALM-2 trial missed the same endpoint at the same dose; the 25 mg low dose showed no significant benefit in either study, and key secondary endpoints including patient-reported cough diary scores also failed to meet their targets. Overall safety was favorable, with adverse events comparable to placebo, but pooled efficacy data showed only a limited effect that would not materially improve the existing treatment landscape.

The drug was the core pipeline of Bellus, acquired by GSK for USD 2 billion, and had been viewed as a candidate to address the unmet need in refractory cough. The discontinuation is a setback for the P2X3 antitussive field; the company will continue clinical development in the irritable bowel syndrome (IBS) indication.

Domestic TYK2 Inhibitor Milestone: InnoCare’s Soficitinib Meets Phase 3 Endpoint in Atopic Dermatitis

On 15 July, InnoCare Pharma announced that its Phase 3 registrational trial of soficitinib (ICP-332), a highly selective oral TYK2 inhibitor developed in-house, has successfully met the primary endpoint in adult patients with moderate-to-severe atopic dermatitis. This multicenter, randomized, double-blind, placebo-controlled trial enrolled 579 patients; the data show statistically significant and clinically meaningful benefit, with all key secondary endpoints also met — including rapid improvement in skin lesions, marked relief of severe pruritus, and significant improvement in patient quality of life. The drug has very high selectivity for TYK2, and compared with traditional pan-JAK inhibitors, the safety advantage is notable, with no new safety risk signals observed in the trial. The asset has a broad dermatology autoimmune pipeline, with parallel clinical development in vitiligo, urticaria, prurigo nodularis, and other indications. The company will complete long-term follow-up and subsequently file for marketing approval; soficitinib is expected to fill the gap in domestic oral TYK2 therapy for atopic dermatitis, offering a convenient oral treatment with improved safety for patients with chronic relapsing dermatitis.

Capital and Deals

NewCo Model Validated Again: Hengrui’s Cardiovascular NewCo Braveheart Heads for Nasdaq IPO

Recently, Braveheart Bio filed an IPO prospectus with the U.S. Securities and Exchange Commission (SEC), planning to list on Nasdaq, with proceeds to be used entirely for global Phase 3 development of its core asset, BHB-1893. This follows the April Nasdaq listing of Hengrui’s GLP-1 NewCo Kailera, and represents another landmark event in Hengrui Pharma’s overseas-licensing NewCo model.

In 2025, Hengrui out-licensed the ex-Greater-China global exclusive rights of its in-house cardiac myosin inhibitor HRS-1893 (BHB-1893) to Braveheart, in a deal with potential total value exceeding USD 1 billion, comprising an upfront payment, clinical and sales milestones, and tiered sales royalties; Hengrui simultaneously received equity in the partner, achieving long-term value alignment. Braveheart has completed a USD 185 million Series A financing, drawing in leading global healthcare investors including OrbiMed and Andreessen Horowitz (a16z); its core asset targets hypertrophic cardiomyopathy (HCM), and overseas Phase 3 trials are about to begin.

The filing further demonstrates the maturity of Hengrui’s NewCo path to overseas markets: rather than a traditional one-time licensing deal, the NewCo model uses an independently listed overseas vehicle to mobilize global capital to share development costs, while sharing in the value appreciation of the asset’s commercialization, providing a replicable template for international business development (BD) of domestic innovative drugs.

Two Major Deals in Two Days: Insilico Medicine Continues to Expand AI Pharma Commercial Footprint

On 13 and 15 July, Insilico Medicine announced two large industry collaborations in succession, accelerating the commercialization of its AI drug discovery business. On 13 July, the company signed a CNS-focused AI new drug discovery collaboration with China Medical System based on its proprietary target-discovery platform PandaOmics, to identify novel mechanisms of action and develop innovative drugs for CNS indications with significant market potential. Insilico may receive up to CNY 1.2 billion in milestone payments and sales royalties; this is the second deep collaboration between the two parties in the year.

On 15 July, Insilico announced a multi-dimensional strategic alliance with Bora Pharmaceuticals, a global pharmaceutical contract development and manufacturing organization (CDMO) leader, integrating Insilico’s end-to-end Pharma.AI R&D capabilities with Bora’s strengths in global development, manufacturing, and commercialization. The two parties will negotiate a formal agreement; if fully executed, the total potential value of the collaboration could exceed USD 2.5 billion. The back-to-back large deals confirm that Insilico’s AI pharma platform is increasingly recognized by domestic and international pharma companies for its commercial value. The company has built a full-chain collaboration pathway spanning target discovery, molecule design, clinical development, and large-scale manufacturing, providing a mature commercial template for AI-driven drug discovery.

USD 600 Million Upfront Sets a New Record: Dizal Out-Licenses Global Exclusive Rights of Sunvozertinib to AstraZeneca

On 14 July, Dizal Pharmaceutical announced a license agreement with AstraZeneca granting the latter global exclusive development and commercialization rights to Dizal’s in-house lung cancer targeted therapy sunvozertinib. The transaction has a potential total value of up to USD 1.5 billion, with a USD 600 million upfront payment — a new record for an upfront payment in an overseas licensing deal for a domestic small-molecule targeted therapy.

Sunvozertinib is a highly selective EGFR tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC); it has already received later-line approvals in both China and the United States, and its first-line Phase 3 data are highly promising, supporting broad global market potential. The transaction consideration includes up to USD 400 million in clinical milestones and USD 500 million in sales milestones; Dizal is also eligible for tiered double-digit sales royalties. AstraZeneca is a related party of Dizal, making this a related-party transaction. Through AstraZeneca’s global commercialization channels, sunvozertinib’s overseas clinical advancement and market uptake are expected to accelerate; the large BD deal also fully validates the global clinical and commercial value of a first-in-class Chinese lung cancer drug.

Domestic Autoimmune Drug Goes Global: Innovent Out-Licenses IBI355 Overseas Exclusive Rights to Spero for USD 1.1 Billion Total

On 14 July, Innovent Biologics announced the progress of a BD collaboration: the company has out-licensed the ex-Greater-China global exclusive rights for research, development, manufacturing, and commercialization of its in-house third-generation anti-CD40L monoclonal antibody IBI355 to Spero. The transaction has a total value of approximately USD 1.1 billion; Innovent will receive an upfront payment and is eligible for milestone payments tied to development, regulatory, and commercial stages, as well as tiered royalties on net sales after launch. IBI355 targets the CD40L pathway, with a focus on autoimmune diseases; its differentiated design may improve on the safety profile of existing products in the same class and holds broad overseas clinical potential.

0
0
Loading